RT Journal Article
SR Electronic
T1 Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1000
OP 1006
DO 10.1136/ijgc-00009577-200605000-00008
VO 16
IS 3
A1 E. Y. Cho
A1 Y. L. Choi
A1 S. W. Chae
A1 J. H. Sohn
A1 G. H. Ahn
YR 2006
UL http://ijgc.bmj.com/content/16/3/1000.abstract
AB We studied the immunoexpression of p14ARF, MDM2, and p53, in addition to relationships between those protein expressions and estrogen receptor (ER)α in ovarian serous tumors including benign (n = 23), borderline (n = 41), and malignant (n = 94). The aberrant expressions of p14ARF, MDM2, and p53 were observed in 19.6% (31/158), 47.5% (75/158), and 39.9% (63/158) of cases, respectively. The expression of MDM2 was significantly higher in borderline tumors compared to benign (P = 0.04) and malignant (P < 0.01) tumors. p53 expression in borderline tumors was uncommon, and p14ARF expression loss was mainly observed in carcinomas. Altered expression of p14ARF, MDM2, and p53 shows significant relationship with stage. Overexpression of MDM2 (P = 0.01) and loss of p14ARF expression (P = 0.04) were significantly associated with ER expression. Our results suggest that alteration of p14ARF–MDM2–p53 pathway proteins may contribute significantly to the tumorigenesis of ovarian serous neoplasms, and ER is involved in cellular regulation of p14ARF–MDM2–p53 pathway in ovarian serous neoplasms.